World Equity Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

World Equity Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,155	Closed	-$767K	–	261
2024 Q2	$767K	Hold	3,155	–	–	0.23%	113
2024 Q1	$472K	Buy	3,155 +142	+5%	+$23.7K	0.1%	194
2023 Q4	$577K	Sell	3,013 -380	-11%	-$64.7K	0.12%	176
2023 Q3	$601K	Buy	3,393 +333	+11%	+$63.5K	0.12%	179
2023 Q2	$581K	Sell	3,060 -30,380	-91%	-$6.02M	0.17%	154
2023 Q1	$863K	Buy	33,440 +30,466	+1,024%	+$6.4M	0.13%	183
2022 Q4	$707K	Sell	2,974 -31	-1%	-$6.61K	0.17%	140
2022 Q3	$601K	Sell	3,005 -44	-1%	-$8.39K	0.15%	142
2022 Q2	$445K	Sell	3,049 -47	-2%	-$6.67K	0.11%	200
2022 Q1	$506K	Buy	+3,096	New	+$472K	0.11%	210

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

World Equity Group's ALNY Position: Q3 2024 in Review

World Equity Group sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2024, closing a stake of 3,155 shares — an estimated $767K sold.

World Equity Group first reported a position in ALNY in Q1 2022 and held it in 10 quarters. The position peaked at $863K in Q1 2023. 567 funds tracked by Wall St. Rank hold ALNY as of Q3 2024.

World Equity Group reported no remaining Alnylam Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
World Equity Group sold 3,155 Alnylam Pharmaceuticals shares in Q3 2024, an estimated $767K.
World Equity Group first reported a position in Alnylam Pharmaceuticals in Q1 2022 and held it in 10 quarters.
World Equity Group's Alnylam Pharmaceuticals position peaked at $863K in Q1 2023.
567 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2024.

Based on World Equity Group's 13F filing for Q3 2024, filed 30 Oct 2024.